

Variant: NM\_033508.3:c.686G>A

Version: 1.1

CA367400776 [↗](#)

2628366 (ClinVar) [↗](#)

**Gene:** GCK ([HGNC:2645](#))

**Condition:** monogenic diabetes ([MONDO:0015967](#))

**Inheritance Mode:** Semidominant inheritance

**UUID:** 696d9e69-b348-4fef-b761-af0194764032

**Approved on:** 2023/11/22

**Published on:** 2023/11/22

## HGVS expressions

### NM\_033508.3:c.686G>A

NC\_000007.14:g.44147824C>T  
CM000669.2:g.44147824C>T  
NC\_000007.13:g.44187423C>T  
CM000669.1:g.44187423C>T  
NC\_000007.12:g.44153948C>T  
NG\_008847.1:g.46600G>A  
NG\_008847.2:g.55347G>A  
ENST00000395796.8:c.\*687G>A  
ENST00000616242.5:c.689G>A  
ENST00000345378.7:c.692G>A  
ENST00000403799.8:c.689G>A  
ENST00000671824.1:c.689G>A  
ENST00000673284.1:c.689G>A  
ENST00000345378.6:c.692G>A  
ENST00000395796.7:c.686G>A  
ENST00000403799.7:c.689G>A  
ENST00000437084.1:c.638G>A  
ENST00000616242.4:c.686G>A  
NM\_000162.3:c.689G>A  
NM\_033507.1:c.692G>A  
NM\_033508.1:c.686G>A  
NM\_000162.4:c.689G>A  
NM\_001354800.1:c.689G>A  
NM\_033507.2:c.692G>A  
NM\_033508.2:c.686G>A  
NM\_000162.5:c.689G>A  
NM\_033507.3:c.692G>A

**Pathogenic**

Met criteria codes **7**

PP1\_Strong PP2 PP3 PM1  
PS4\_Moderate PM2\_Supporting  
PP4\_Moderate

Evidence Links **0**

Expert Panel

Monogenic Diabetes VCEP [↗](#)

Criteria Specification Information

Evidence submitted by expert panel

Monogenic Diabetes VCEP

The c.689G>A variant in the glucokinase gene, GCK, causes an amino acid change of cysteine to tyrosine at codon 230 (p.(Cys230Tyr)) of NM\_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant resides in an amino acid that directly binds glucose, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1), and is predicted to be deleterious by computational evidence, with a REVEL score of 0.966, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent in gnomAD v2.1.1 (PM2\_Supporting). This variant was identified in 5 unrelated individuals with hyperglycemia (PS4\_Moderate; PMIDs: 3547291, 30663027, 25306193, internal lab contributors), including an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4\_Moderate; PMID: 35472491, internal lab contributors). This variant segregated with diabetes/hyperglycemia, with 8 informative meioses in a 3 families (PP1\_Strong; PMID: 35472491, internal lab contributors). In summary, the c.689G>A variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PP1\_Strong, PP4\_Moderate, PS4\_Moderate, PM1, PP2, PP3, PM2\_Supporting.

Met criteria codes

|                |                                                                                     |                                                                                     |                                                                                                                                                                                                                                       |
|----------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PP1_Strong     |  |  | This variant segregated with diabetes/hyperglycemia, with 8 informative meioses in a 3 families (PMID: 35472491, internal lab contributors).                                                                                          |
| PP2            |  |  | GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).                                                            |
| PP3            |  |  | This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.966, which is greater than the MDEP VCEP threshold of 0.70 (PP3).                                                                      |
| PM1            |  |  | This variant resides in an amino acid that directly binds glucose, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1).                                                                                 |
| PS4_Moderate   |  |  | This variant was identified in 5 unrelated individuals with hyperglycemia (PS4_Moderate; PMIDs: 3547291, 30663027, 25306193, internal lab contributors).                                                                              |
| PM2_Supporting |  |  | This variant is absent in gnomAD v2.1.1 (PM2_Supporting).                                                                                                                                                                             |
| PP4_Moderate   |  |  | This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; PMID: 35472491, internal lab contributors). |

▼

▼

Showing 1 to 2 of 2 rows

|  |
|--|
|  |
|--|

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.